Zobrazeno 1 - 10 of 28 pro vyhledávání: '"Alberto Bernareggi"'
1
Akademický článek
Oral Liquid Formulation of Levothyroxine Is Stable in Breakfast Beverages and May Improve Thyroid Patient Compliance
Autor: Alberto Bernareggi, Elia Grata, Maria Teresa Pinorini, Ario Conti
Publikováno v: Pharmaceutics, Vol 5, Iss 4, Pp 621-633 (2013)
Patients on treatment with levothyroxine (T4) are informed to take this drug in the morning, at least 30 min before having breakfast. A significant decrease of T4 absorption was reported, in fact, when T4 solid formulations are taken with food or cof
Externí odkaz: https://doaj.org/article/39eb02fa5e6a463fa34441b71dc44318
Zobrazit plný text záznamu
3
Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study
Autor: Salvatore Chessari, Hongyun Wang, Alberto Bernareggi, Wen Zhong, Rui Chen, Corinna Lanzarotti, Pei Hu
Publikováno v: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 160
Purpose Palonosetron hydrochloride is a specific 5-HT3 receptor antagonist, used to prevent chemotherapy-induced nausea and vomiting (CINV), and is a known chemical entity currently registered in the oral and IV forms in several countries worldwide.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14dd80162b5d66d478e519d6331fa8f9
https://pubmed.ncbi.nlm.nih.gov/33581259
Zobrazit plný text záznamu
4
A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers
Autor: Salvatore Chessari, Wen Zhong, Corinna Lanzarotti, Hongyun Wang, Alberto Bernareggi, Rui Chen, Pei Hu
Publikováno v: Cancer chemotherapy and pharmacology. 87(3)
Oral NEPA, the only fixed-combination antiemetic, is composed of the neurokinin-1 receptor antagonist netupitant (300 mg) and the 5-hydroxytryptamine-3 receptor antagonist palonosetron (0.50 mg). This study was conducted to evaluate the pharmacokinet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e644da8c9c87d4aac9dd270d95f882c
https://pubmed.ncbi.nlm.nih.gov/33386423
Zobrazit plný text záznamu
5
Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
Autor: Matti Aapro, Sally Baron-Hay, Alberto Bernareggi, Lee S. Schwartzberg
Publikováno v: Supportive Care in Cancer
Purpose The administration timing of antiemetic and chemotherapeutic regimens is often determined by regulatory indications, based on registration studies. Oral NEPA, fixed combination of the neurokinin-1 receptor antagonist (NK1RA) netupitant and th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a035008388d8d92ff5fc5741698d00b
https://doi.org/10.1007/s00520-019-4640-8
Zobrazit plný text záznamu
6
Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Autor: James Gilmore, Alberto Bernareggi
Publikováno v: Journal of Clinical Pharmacology
NEPA is the first fixed‐combination antiemetic composed of the neurokinin‐1 receptor antagonist netupitant (netupitant; 300 mg) and the 5‐hydroxytryptamine‐3 receptor antagonist palonosetron (palonosetron; 0.50 mg). This study evaluated the p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb693bbe988546437fbc68db97a6515e
https://doi.org/10.1002/jcph.1338
Zobrazit plný text záznamu
8
Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
Autor: Alberto Bernareggi, Nataliya P. Chilingirova, Giada Rizzi, Tatiana Caccia, Valentino J. Stella, Galina Kurteva
Publikováno v: European Journal of Pharmaceutical Sciences. 139:105041
NEPA is the fixed combination antiemetic composed of the neurokinin-1 receptor antagonist netupitant and the 5-hydroxytryptamine-3 receptor antagonist palonosetron. The intravenous (i.v.) formulation of NEPA (fosnetupitant 235 mg/palonosetron 0.25 mg
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7993e523a474c0cf752113383202f05
https://doi.org/10.1016/j.ejps.2019.105041
Zobrazit plný text záznamu
9
Oral Liquid Formulation of Levothyroxine Is Stable in Breakfast Beverages and May Improve Thyroid Patient Compliance
Autor: Maria Teresa Pinorini, Ario Conti, Alberto Bernareggi, Elia Grata
Publikováno v: Pharmaceutics, Vol 5, Iss 4, Pp 621-633 (2013)
Pharmaceutics
Pharmaceutics; Volume 5; Issue 4; Pages: 621-633
Patients on treatment with levothyroxine (T4) are informed to take this drug in the morning, at least 30 min before having breakfast. A significant decrease of T4 absorption was reported, in fact, when T4 solid formulations are taken with food or cof
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54281926ca7f3839a87dce69e450844f
http://www.mdpi.com/1999-4923/5/4/621
Zobrazit plný text záznamu
10
Effects of strong cytochrome P450 (CYP)3A4 inducers/inhibitors on the pharmacokinetic (PK) profile of anamorelin in healthy volunteers
Autor: Alberto Bernareggi, Elizabeth Manning Duus, Mark A. Matson
Publikováno v: Journal of Clinical Oncology. 36:e22180-e22180
e22180Background: Anamorelin is an oral selective ghrelin receptor agonist in development that showed benefits for patients with advanced non-small cell lung cancer and anorexia/cachexia (ROMANA st...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44f231a0ddb1b717248e36a9523fd635
https://doi.org/10.1200/jco.2018.36.15_suppl.e22180
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje